Orphenadrine Hcl
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01173 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 25 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 2 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 3 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 4 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 5 | schizophrenia | KG + DL |
| 6 | myopia X-linked | KG + DL |
| 7 | myopia 26, X-linked, female-limited | KG + DL |
| 8 | syndromic myopia | KG + DL |
| 9 | atypical glycine encephalopathy | KG + DL |
| 10 | hydranencephaly (disease) | KG + DL |
| 11 | paralysis agitans, juvenile, of Hunt | KG + DL |
| 12 | lethal infantile mitochondrial myopathy | KG + DL |
| 13 | PLA2G6-associated neurodegeneration | KG + DL |
| 14 | hereditary late onset Parkinson disease | KG + DL |
| 15 | X-linked parkinsonism-spasticity syndrome | KG + DL |
| 16 | Lewy body dementia | KG + DL |
| 17 | progressive supranuclear palsy-corticobasal syndrome | KG + DL |
| 18 | atypical juvenile parkinsonism | KG + DL |
| 19 | hemiparkinsonism-hemiatrophy syndrome | KG + DL |
| 20 | autosomal recessive Parkinson disease | KG + DL |
| 21 | schizophreniform disorder | KG + DL |
| 22 | juvenile onset Parkinson disease 19A | KG + DL |
| 23 | myelitis | KG + DL |
| 24 | Rasmussen subacute encephalitis | KG + DL |
| 25 | early-onset parkinsonism-intellectual disability syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.